Eileen Del Carmen Maurad Farfán

Eileen Del Carmen Maurad Farfán

Auto-generated profile, based on publicly available information

Eileen Del Carmen Maurad Farfán

Investigador Independiente

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Salud Medicina e Innovación Journal
Verified
Journal Article
Open access
PDF file
EFEileen Del Carmen Maurad Farfán
Eileen Del Carmen Maurad Farfán
AVAngie Daniela Beltrán Vera
Angie Daniela Beltrán Vera
EPEduardo Enrique Viteri Parraga
Eduardo Enrique Viteri Parraga
APArleth Bianka Sánchez Pacheco
Arleth Bianka Sánchez Pacheco
JGJosé Luis Ordóñez Galiano
José Luis Ordóñez Galiano
La psoriasis es reconocida actualmente como una enfermedad inflamatoria sistémica con implicaciones significativas más allá de la piel. Los pacientes presentan un mayor riesgo de enfermedades cardiovasculares y renales crónicas, impulsado por vías inflamatorias compartidas. La llegada de terapias sistémicas dirigidas, particularmente los biológicos, ofrece una oportunidad única para modificar este riesgo. Esta revisión sistemática sintetiza la evidencia actual sobre el impacto de la terapia dermatológica sistémica antiinflamatoria en los resultados cardiovasculares y renales en pacientes con psoriasis, abogando por un modelo de atención multidisciplinario. Se realizó una búsqueda bibliográfica exhaustiva en PubMed, Scopus y Web of Science desde su inicio hasta 2025. La evidencia creciente sugiere que el tratamiento sistémico eficaz, especialmente con biológicos, se asocia con la estabilización de la aterosclerosis subclínica, la mejora de la función vascular y la reducción de la incidencia de eventos cardiovasculares adversos mayores. De manera similar, ciertas terapias pueden mitigar la progresión del deterioro renal. Los beneficios parecen extenderse más allá del aclaramiento cutáneo, correlacionándose con la reducción de la inflamación sistémica. Un enfoque multidisciplinario Dermato‑Cardio‑Nefrológico es fundamental para abordar de manera integral la carga sistémica de la enfermedad.

1 July 2026 in Salud Medicina e Innovación Journal
Verified
Journal Article
Open access
PDF file
EFEileen Del Carmen Maurad Farfán
Eileen Del Carmen Maurad Farfán
EPEduardo Enrique Viteri Parraga
Eduardo Enrique Viteri Parraga
JVJennifer Gabriela Monar Villavicencio
Jennifer Gabriela Monar Villavicencio
APArleth Bianka Sánchez Pacheco
Arleth Bianka Sánchez Pacheco
JGJosé Luis Ordóñez Galiano
José Luis Ordóñez Galiano
LJLizbeth Alexandra Angamarca Jara
Lizbeth Alexandra Angamarca Jara
Introduction: Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology affecting infants and young children, being extremely rare in neonates and particularly uncommon in its afebrile form (Shen et al., 2024). Refractory KD, defined by persistent or recurrent fever 36 hours after completing intravenous immunoglobulin (IVIG) treatment, affects 15-20% of patients and is associated with high risk of giant coronary aneurysms (Tsoi et al., 2025). Giant coronary aneurysms (Z-score ≥ 10) can complicate with thrombosis, myocardial ischemia, and sudden death (Shrivastava et al., 2026). Mesenteric vasculitis can cause ischemic small bowel strictures, an exceptional complication documented in isolated cases (Beiler et al., 2001; Murphy et al., 1987). Generalized exfoliative dermatitis can present as an atypical manifestation of KD or as a differential diagnosis (Mohammadsaeed & Saeed, 2014). Objective: To synthesize the available evidence on refractory KD in neonates with giant coronary aneurysms, intestinal ischemia due to vasculitis, and generalized exfoliative dermatitis. Methodology: Systematic review following PRISMA 2020 guidelines (Page et al., 2021). A systematic search was conducted in PubMed, LILACS, SciELO and Cochrane for studies published between 1980 and 2026 on refractory KD, giant coronary aneurysms, ischemic gastrointestinal complications, and exfoliative dermatitis. Results: Eight relevant studies were identified. KD in infants under 3 months represents 1.67% of cases and presents higher risk of giant aneurysms (Shrivastava et al., 2026). Infants under 6 months have higher incidence of incomplete KD and diagnostic delay (Shrivastava et al., 2026; Shen et al., 2024). Options for refractory KD include second IVIG dose, methylprednisolone (30 mg/kg/dose), and infliximab (5 mg/kg) (Tsoi et al., 2025). Intestinal ischemia due to mesenteric vasculitis has been documented in cases of incomplete KD, with jejunal stricture and obstruction (Beiler et al., 2001; Murphy et al., 1987). Generalized exfoliative dermatitis can be a manifestation of KD or drug-induced (Mohammadsaeed & Saeed, 2014). Conclusion: Refractory KD in neonates is an exceptional but potentially devastating entity, characterized by rapid progression to giant coronary aneurysms, thrombotic complications, and multisystemic ischemia. Early diagnosis and aggressive treatment with multiple therapeutic lines are essential to reduce associated morbidity and mortality.

1 July 2026 in Salud Medicina e Innovación Journal
Verified
Journal Article
Open access
PDF file
EFEileen Del Carmen Maurad Farfán
Eileen Del Carmen Maurad Farfán
DODiana Elizabeth Caicedo Oleas
Diana Elizabeth Caicedo Oleas
SZSergio Antonio Villavicencio Zambrano
Sergio Antonio Villavicencio Zambrano
BVByron Fernando Quituisaca Vizhñay
Byron Fernando Quituisaca Vizhñay
KFKatty Carola Salinas Flores
Katty Carola Salinas Flores
Introduction: Thromboangiitis obliterans (TAO) is a non-atherosclerotic inflammatory vasculopathy affecting small and medium-sized vessels, typically in young male smokers, with a significant immune component evidenced by the presence of antineutrophil cytoplasmic antibodies (ANCA) in up to 55-73% of patients (Guo et al., 2013; Halbritter et al., 1998). Overlap with ANCA-associated vasculitis (AAV) is rare but documented (ACP Clinical Cases, 2024). Immune checkpoint inhibitors (ICIs) can trigger fulminant myocarditis, with <1% incidence but high mortality (Vyas et al., 2026). Objective: To synthesize the available evidence on polyvascular TAO, its overlap with AAV, the presence of ANCA, and ICI-induced myocarditis. Methodology: Systematic review following PRISMA 2020 guidelines (Page et al., 2021). A systematic search was conducted in PubMed and other sources for studies published between 1986 and 2026 on TAO, AAV, ANCA and ICI-induced myocarditis. Results: Eight relevant studies were identified. TAO can present with polyvascular involvement, including coronary involvement in 14.3% of cases (Kelemen et al., 2016). AAV-TAO overlap has been documented with positive ANCA and pauci-immune glomerulonephritis (ACP Clinical Cases, 2024). ANCA are present in 55-73% of TAO patients, correlating with disease severity (Guo et al., 2013; Halbritter et al., 1998). ICI-induced myocarditis can present fulminantly, with cardiac biomarker elevation and corticosteroid response (Vyas et al., 2026). Conclusion: Polyvascular TAO represents a destructive paradigm combining thrombotic vascular inflammation, systemic autoimmunity, and immune-mediated myocardial vulnerability, requiring a multidisciplinary diagnostic and therapeutic approach.